GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$3.35 USD
-0.41 (-10.84%)
Updated Apr 26, 2024 03:13 PM ET
After-Market: $3.21 -0.14 (-4.04%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
GT Biopharma, Inc. [GTBP]
Reports for Purchase
Showing records 1 - 20 ( 70 total )
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Landscape Updates From ASH Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
GTB-3650 Expected to Enter Clinic in Early 2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Landscape Updates From ASCO Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Solid Tumor TriKE Data Presented; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results For GTB-5550 Presented; Competitor Datasets From ESMO; Modulating PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: GT Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Pushes Back Filings For TriKE Clinical Programs. Rating to NEUTRAL.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T